{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:52:41Z","timestamp":1792036361342,"version":"4.4.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.radonc.2026.111515","type":"journal-article","created":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T23:24:44Z","timestamp":1774826684000},"page":"111515","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Optimizing low dose radiotherapy for indolent lymphomas: comparing 8\u00a0Gy in 2 fractions to 4\u00a0Gy in 2 fractions"],"prefix":"10.1016","volume":"219","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8653-1045","authenticated-orcid":false,"given":"Jessica F.","family":"Burlile","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William S.","family":"Harmsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3193-4565","authenticated-orcid":false,"given":"Sydney D.","family":"Suddendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey M.","family":"Frechette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9400-4771","authenticated-orcid":false,"given":"Omran","family":"Saifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel R.","family":"Kosydar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Habermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.C.","family":"Villasboas Bisneto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1292-3024","authenticated-orcid":false,"given":"Paul","family":"Hampel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7350-5531","authenticated-orcid":false,"given":"Jonas","family":"Paludo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2312-5418","authenticated-orcid":false,"given":"Bradford S.","family":"Hoppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9379-4732","authenticated-orcid":false,"given":"Randa","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Rule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana N.","family":"Micallef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Breen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5264-9811","authenticated-orcid":false,"given":"Scott C.","family":"Lester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2026.111515_b0005","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijrobp.2014.01.006","article-title":"Modern radiation therapy for nodal non-hodgkin lymphoma\u2014target definition and dose guidelines from the international lymphoma radiation oncology group","volume":"89","author":"Illidge","year":"2014","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111515_b0010","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/0360-3016(86)90057-X","article-title":"Prognostic factors in non-Hodgkin\u2019s lymphoma","volume":"12","author":"Tubiana","year":"1986","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111515_b0015","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","article-title":"Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial","volume":"100","author":"Lowry","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111515_b0020","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.2003.09.542","article-title":"High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas","volume":"21","author":"Haas","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111515_b0025","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0360-3016(01)01626-1","article-title":"A high and sustained response rate in refractory or relapsing low-grade lymphoma masses after low-dose radiation: analysis of predictive parameters of response to treatment","volume":"51","author":"Girinsky","year":"2001","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111515_b0030","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S1470-2045(20)30686-0","article-title":"4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial","volume":"22","author":"Hoskin","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111515_b0035","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1002\/cam4.2796","article-title":"Repeated courses of low-dose 2\u00d72Gy radiation therapy in patients with indolent B-cell non-Hodgkin lymphomas","volume":"9","author":"Saleh","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.radonc.2026.111515_b0040","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1182\/blood.2024026018","article-title":"Treatment of relapsed and refractory follicular lymphoma: which treatment for which patient for which line of therapy?","volume":"146","author":"Casulo","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.radonc.2026.111515_b0045","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(24)00133-9","article-title":"Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma: a single-centre, pilot trial","volume":"11","author":"Gunther","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.radonc.2026.111515_b0050","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/jamaoncol.2024.2112","article-title":"Response-adapted ultralow-dose radiation therapy for orbital indolent B-cell lymphoma: a phase 2 nonrandomized controlled trial","volume":"10","author":"Pinnix","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2026.111515_b0055","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/ajh.26968","article-title":"Cutaneous B-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Hristov","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.radonc.2026.111515_b0060","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijrobp.2015.01.008","article-title":"International lymphoma radiation oncology group. modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the international lymphoma radiation oncology group","volume":"92","author":"Specht","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111515_b0065","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/jvc2.403","article-title":"Ultra-low dose radiation therapy for primary cutaneous indolent B-cell lymphomas","volume":"3","author":"Kasera","year":"2024","journal-title":"JEADV Clin Pract"},{"key":"10.1016\/j.radonc.2026.111515_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.111327","article-title":"Low-dose radiotherapy for primary cutaneous indolent B-cell lymphomas: a multicenter retrospective study","volume":"215","author":"Al\u00ec","year":"2026","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111515_b0075","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.1016\/S2352-3026(25)00071-7","article-title":"Low-dose moderate hypofractionated radiotherapy for indolent non-Hodgkin lymphoma: a multicentre, single-arm, phase 2 trial","volume":"12","author":"Wang","year":"2025","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.radonc.2026.111515_b0080","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1182\/bloodadvances.2021004939","article-title":"Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: is 4 Gy suitable for curable patients?","volume":"5","author":"Imber","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.radonc.2026.111515_b0085","unstructured":"Sunnybrook Health Sciences Centre. A Phase II Trial of Intermediate Radiation Dose For Low Grade Follicular Lymphoma. clinicaltrials.gov; 2024."},{"key":"10.1016\/j.radonc.2026.111515_b0090","unstructured":"Mayo Clinic. Reduced Dose Hypofractionated Radiotherapy (3Gy x 3 Fractions) for Indolent Non-Hodgkin Lymphoma (POSEIDON): A Multisite Phase 2 Randomized Trial. clinicaltrials.gov; 2025."},{"key":"10.1016\/j.radonc.2026.111515_b0095","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.semradonc.2007.02.006","article-title":"Low-grade non-hodgkin lymphomas","volume":"17","author":"Tsang","year":"2007","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111515_b0100","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/hed.24717","article-title":"Ultra\u2013low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma","volume":"39","author":"Pinnix","year":"2017","journal-title":"Head Neck"},{"key":"10.1016\/j.radonc.2026.111515_b0105","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.ijrobp.2025.03.011","article-title":"An international lymphoma radiation oncology group study of radiation therapy for bilateral indolent orbital adnexal lymphomas","volume":"122","author":"Tran","year":"2025","journal-title":"Int J Radiat Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026001544?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026001544?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:06:33Z","timestamp":1789751193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814026001544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":21,"alternative-id":["S0167814026001544"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111515","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing low dose radiotherapy for indolent lymphomas: comparing 8\u00a0Gy in 2 fractions to 4\u00a0Gy in 2 fractions","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111515","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111515"}}